Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 pediatric study of ibrutinib for chronic graft-versus-host disease
MOH_2019-11-29_008526Phase 2Active, not recruiting
- Sponsor
- Pharmacyclics
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibrutinib in chronic graft-versus-host disease (cGVHD) (2 arms), sponsored by Pharmacyclics. Primary endpoints: Recommended pediatric dose and Safety. Started Nov 2019; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on MOH_2019-11-29_008526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-11-29_008526.